Market Chameleon (Thu, 18-Dec 4:37 AM ET)
Biodexa Announces Pricing of $10 Million Public Offering
Globe Newswire (Thu, 18-Dec 8:30 AM ET)
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Globe Newswire (Mon, 1-Dec 8:30 AM ET)
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Globe Newswire (Mon, 24-Nov 8:30 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
Globe Newswire (Mon, 3-Nov 8:30 AM ET)
Globe Newswire (Mon, 6-Oct 8:30 AM ET)
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Biodexa Pharmaceuticals PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BDRX.
As of December 26, 2025, BDRX stock price declined to $2.63 with 448,862 million shares trading.
BDRX has a beta of 0.20, meaning it tends to be less sensitive to market movements. BDRX has a correlation of 0.00 to the broad based SPY ETF.
BDRX has a market cap of $2.21 million. This is considered a Sub-Micro Cap stock.
BDRX has underperformed the market in the last year with a price return of -94.4% while the SPY ETF gained +16.0%. BDRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -58.6% and -44.6%, respectively, while the SPY returned +4.6% and +1.5%, respectively.
BDRX support price is $2.37 and resistance is $3.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDRX shares will trade within this expected range on the day.
